

1636
#7
11/27/02

Docket No.: 50193-1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Salah D. KLIVIGHN, et al.

Serial No.: 09/892,505

Filed: June 28, 2001

For: PRODUCTION METHOD OF PATTERN FOR CASTING

:
:
:
:
:
:
:

Group Art Unit: 1636

Examiner: Nguyen, Quang

RECEIVED

NOV 25 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

CERTIFICATION PARAGRAPH

The undersigned certifies that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any

Serial No.: 09/892,505

individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(2).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.


Respectfully submitted,

MCDERMOTT, WILL & EMERY



Robert L. Price
Registration No. 22,685

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 RLP:prp
Facsimile: (202) 756-8087
Date: November 22, 2002

INFORMATION DISCLOSURE CITATION IN AN APPLICATION 				ATTY. DOCKET NO. 50193-109		SERIAL NO. 09/892,505			
				APPLICANT Salah D. KIVLIGHN, et al.				NOV 25 2002	
				FILING DATE June 28, 2001		GROUP 1636		TECH CENTER 1600/290	
U.S. PATENT DOCUMENTS									
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE			
/S.K./	5,260,322	11/9/1993	Nakasima et al.						
FOREIGN PATENT DOCUMENTS									
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation			
						Yes	No		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
<i>pk</i>	Alderman, M.H. et al, "Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients", Hypertension 34:144-150 (1999).								
	Fang, J. et al, "Serum Uric Acid and Cardiovascular Mortality", The NHANES I Epidemiologic Follow-up Study, 1971-1992, JAMA 283:2404-2410 (2000).								
	Landmesser, U. et al., "Oxidative stress and vascular damage in hypertension", Coronary Artery Disease, 2001, Sep.; 12, (6): 455-461.								
	Maxwell, Simon et al., "Anti-oxidants-a protective role in cardiovascular disease?", Expert Opinion, Pharmacother., 2001, Nov.; 2(11): 1737-1750.								
	Marilda Mazzali, et al., "Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism", pp. 1101-1106. <i>Date 1/14/03</i>								
<i>pk</i>	Nakashima, M., "Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects", Eur J. Clin Pharmacol (1992), 42: 333-335.								
	Nakazono, K. et al., "Does superoxide underlie the pathogenesis of hypertension?", Proc. Natl. Acad. Sci., 88: 10045-10048, 1991.								
	Pui, Ching-Hon et al., "Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma", J. Clin. Oncol., (2001), 19: 697-704.								
	Sowers, J.R., "Hypertension, Angiotensin II, and Oxidative Stress", NEJM, 346: (2002), 1999-2001.								
	Vaziri, N.D. et al., "Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats", American Heart Association, 36: (2000) 957-964.								
	Verdecchia, P. et al., "Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study", American Heart Association, 36: (2000) 1072-1078.								
	Wilcox, C.S., "Reactive Oxygen Species: Roles in Blood Pressure and Kidney Function", Current Hypertension Reports, 2002, 160-6.								
EXAMINER /Shobha Kantamneni/				DATE CONSIDERED 11/20/2008					